John R Mascola

List of Publications by Year
in descending order

384 papers	73,440 citations	435 131 h-index	799 247 g-index
411 all docs	411 docs citations	411 times ranked	43222 citing authors

#	Article	IF	Citations
1	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. Science Translational Medicine, 2022, 14, eabj7125.	12.4	93
2	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. Cell, 2022, 185, 113-130.e15.	28.9	64
3	Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention. Journal of Infectious Diseases, 2022, 226, 510-520.	4.0	13
4	SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. New England Journal of Medicine, 2022, 386, 1088-1091.	27.0	338
5	Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys. Cell Reports, 2022, 38, 110199.	6.4	19
6	Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nature Medicine, 2022, 28, 383-391.	30.7	65
7	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell, 2022, 185, 1556-1571.e18.	28.9	179
8	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. Science, 2022, 376, eabn8897.	12.6	119
9	Development of Neutralization Breadth against Diverse HIVâ€1 by Increasing Abâ€"Ag Interface on V2. Advanced Science, 2022, , 2200063.	11.2	3
10	Antigenic analysis of the HIV-1 envelope trimer implies small differences between structural states 1 and 2. Journal of Biological Chemistry, 2022, 298, 101819.	3.4	9
11	Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nature Medicine, 2022, 28, 1022-1030.	30.7	34
12	LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Reports, 2022, 39, 110812.	6.4	287
13	Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial. Lancet Infectious Diseases, The, 2022, 22, 1210-1220.	9.1	15
14	Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nature Medicine, 2022, 28, 1288-1296.	30.7	44
15	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. PLoS ONE, 2022, 17, e0268767.	2.5	18
16	Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. EClinicalMedicine, 2022, 48, 101477.	7.1	13
17	Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine. Science Translational Medicine, 2022, 14, .	12.4	7
18	Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4. PLoS Pathogens, 2022, 18, e1010574.	4.7	6

#	Article	IF	Citations
19	Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability. Structure, 2022, 30, 1233-1244.e7.	3.3	13
20	Broadly neutralizing antibodies target the coronavirus fusion peptide. Science, 2022, 377, 728-735.	12.6	111
21	Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. New England Journal of Medicine, 2021, 384, 80-82.	27.0	665
22	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. Science, 2021, 371, .	12.6	49
23	Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach. Clinical Pharmacology and Therapeutics, 2021, 109, 184-192.	4.7	6
24	Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. Vaccines, 2021, 9, 73.	4.4	24
25	A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention. MAbs, 2021, 13, 1946918.	5.2	11
26	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine, 2021, 384, 403-416.	27.0	7,910
27	Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. EBioMedicine, 2021, 64, 103203.	6.1	14
28	Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. Science Translational Medicine, 2021, 13, .	12.4	49
29	Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. New England Journal of Medicine, 2021, 384, 1003-1014.	27.0	270
30	Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature, 2021, 592, 623-628.	27.8	180
31	Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature, 2021, 593, 130-135.	27.8	1,904
32	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Science Translational Medicine, 2021, 13, .	12.4	347
33	Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. Immunity, 2021, 54, 769-780.e6.	14.3	37
34	SARS-CoV-2 Viral Variantsâ€"Tackling a Moving Target. JAMA - Journal of the American Medical Association, 2021, 325, 1261.	7.4	165
35	Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1â€"Exposed Newborn Infants. Journal of Infectious Diseases, 2021, 224, 1916-1924.	4.0	27
36	Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. New England Journal of Medicine, 2021, 384, 2259-2261.	27.0	603

#	Article	IF	Citations
37	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science, 2021, 373, .	12.6	174
38	Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques. PLoS Pathogens, 2021, 17, e1009738.	4.7	7
39	InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell, 2021, 184, 4203-4219.e32.	28.9	228
40	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity, 2021, 54, 1636-1651.	14.3	165
41	Blocking Î± ₄ Î² ₇ integrin delays viral rebound in SHIV _{SF162P3} -infected macaques treated with anti-HIV broadly neutralizing antibodies. Science Translational Medicine, 2021, 13, .	12.4	11
42	A Monoclonal Antibody for Malaria Prevention. New England Journal of Medicine, 2021, 385, 803-814.	27.0	95
43	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. Science Translational Medicine, 2021, 13, eabj5413.	12.4	79
44	Durability of mRNA-1273 vaccineâ€"induced antibodies against SARS-CoV-2 variants. Science, 2021, 373, 1372-1377.	12.6	459
45	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science, 2021, 373, eabj0299.	12.6	244
46	Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	20
47	Structurally related but genetically unrelated antibody lineages converge on an immunodominant HIV-1 Env neutralizing determinant following trimer immunization. PLoS Pathogens, 2021, 17, e1009543.	4.7	5
48	Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging. Journal of Clinical Investigation, 2021, 131, .	8.2	1
49	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. New England Journal of Medicine, 2021, 385, 1774-1785.	27.0	402
50	SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity. Journal of Biological Chemistry, 2021, 297, 101127.	3.4	9
51	Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. Lancet Respiratory Medicine,the, 2021, 9, 1111-1120.	10.7	38
52	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccineâ€"boosted nonhuman primates. Science, 2021, 374, 1343-1353.	12.6	83
53	A multiclade envâ€"gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nature Medicine, 2021, 27, 2234-2245.	30.7	80
54	Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine. Frontiers in Immunology, 2021, 12, 772864.	4.8	21

#	Article	IF	Citations
55	Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. Journal of Infectious Diseases, 2020, 222, 628-636.	4.0	38
56	Novel vaccine technologies for the 21st century. Nature Reviews Immunology, 2020, 20, 87-88.	22.7	103
57	Extensive dissemination and intraclonal maturation of HIV Env vaccine-induced B cell responses. Journal of Experimental Medicine, 2020, 217, .	8.5	23
58	Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity. Nature Communications, 2020, 11, 70.	12.8	37
59	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature, 2020, 586, 567-571.	27.8	1,153
60	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. Cell Reports, 2020, 33, 108322.	6.4	59
61	Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18754-18763.	7.1	53
62	An mRNA Vaccine against SARS-CoV-2 â€" Preliminary Report. New England Journal of Medicine, 2020, 383, 1920-1931.	27.0	2,719
63	Development of a potent Zika virus vaccine using self-amplifying messenger RNA. Science Advances, 2020, 6, eaba5068.	10.3	50
64	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. New England Journal of Medicine, 2020, 383, 1544-1555.	27.0	936
65	Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature. Cell Reports, 2020, 32, 107981.	6.4	15
66	Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide. Vaccines, 2020, 8, 765.	4.4	12
67	A strategic approach to COVID-19 vaccine R&D. Science, 2020, 368, 948-950.	12.6	419
68	Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development. Frontiers in Immunology, 2020, 11, 842.	4.8	36
69	Monoclonal Antibodies for Prevention and Treatment of COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 131.	7.4	237
70	Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. Science Translational Medicine, 2020, 12, .	12.4	30
71	VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage. Cell Host and Microbe, 2020, 27, 531-543.e6.	11.0	23
72	Immune checkpoint modulation enhances HIV-1 antibody induction. Nature Communications, 2020, 11, 948.	12.8	27

#	Article	IF	Citations
73	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. PLoS Computational Biology, 2020, 16, e1007626.	3.2	20
74	HIV-1 gp120â€"CD4-Induced Antibody Complex Elicits CD4 Binding Siteâ€"Specific Antibody Response in Mice. Journal of Immunology, 2020, 204, 1543-1561.	0.8	4
75	Next-generation influenza vaccines: opportunities and challenges. Nature Reviews Drug Discovery, 2020, 19, 239-252.	46.4	192
76	Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition. Cell Reports, 2020, 31, 107488.	6.4	53
77	Effect of a Chikungunya Virusâ€"Like Particle Vaccine on Safety and Tolerability Outcomes. JAMA - Journal of the American Medical Association, 2020, 323, 1369.	7.4	68
78	Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial. BMJ Open, 2020, 10, e042247.	1.9	25
79	Title is missing!. , 2020, 16, e1007626.		0
80	Title is missing!. , 2020, 16, e1007626.		0
81	Title is missing!. , 2020, 16, e1007626.		0
82	Title is missing!. , 2020, 16, e1007626.		0
83	A proof of concept for structure-based vaccine design targeting RSV in humans. Science, 2019, 365, 505-509.	12.6	207
84	Delayed vaginal SHIV infection in VRC01 and anti-Î±4Î²7 treated rhesus macaques. PLoS Pathogens, 2019, 15, e1007776.	4.7	16
85	Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization. Cell, 2019, 178, 567-584.e19.	28.9	106
86	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. Nature Communications, 2019, 10, 2898.	12.8	35
87	Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial. BMJ Open, 2019, 9, e030283.	1.9	12
88	Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates. Scientific Reports, 2019, 9, 14696.	3.3	30
89	Multiple roles for HIV broadly neutralizing antibodies. Science Translational Medicine, 2019, 11, .	12.4	144
90	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. Cell Host and Microbe, 2019, 26, 336-346.e3.	11.0	88

#	Article	IF	Citations
91	Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. Lancet HIV,the, 2019, 6, e667-e679.	4.7	67
92	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. PLoS Pathogens, 2019, 15, e1008026.	4.7	56
93	Comparison of adjuvants to optimize influenza neutralizing antibody responses. Vaccine, 2019, 37, 6208-6220.	3.8	16
94	Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet, The, 2019, 393, 889-898.	13.7	99
95	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. Immunity, 2019, 50, 1513-1529.e9.	14.3	85
96	A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates. Science Translational Medicine, 2019, 11, .	12.4	42
97	Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. PLoS ONE, 2019, 14, e0215163.	2.5	41
98	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV,the, 2019, 6, e297-e306.	4.7	73
99	Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages. MBio, 2019, 10, .	4.1	88
100	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. Immunity, 2019, 50, 677-691.e13.	14.3	77
101	Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nature Immunology, 2019, 20, 362-372.	14.5	211
102	Improvement of antibody functionality by structure-guided paratope engraftment. Nature Communications, 2019, 10, 721.	12.8	27
103	Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability. Immunity, 2019, 51, 915-929.e7.	14.3	111
104	Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry. Nature Communications, 2019, 10, 47.	12.8	50
105	Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition. Structure, 2019, 27, 196-206.e6.	3.3	69
106	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host and Microbe, 2019, 25, 59-72.e8.	11.0	124
107	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. Journal of Clinical Investigation, 2019, 129, 4838-4849.	8.2	95
108	Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B. Pathogens and Immunity, 2019, 4, 294.	3.1	26

#	Article	IF	Citations
109	Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. Journal of Virology, 2018, 92, .	3.4	155
110	Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity. Nature Communications, 2018, 9, 877.	12.8	65
111	Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens. ACS Infectious Diseases, 2018, 4, 788-796.	3.8	65
112	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody. Cell Reports, 2018, 22, 1798-1809.	6.4	52
113	Functional interrogation and mining of natively paired human VH:VL antibody repertoires. Nature Biotechnology, 2018, 36, 152-155.	17.5	109
114	Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. Human Vaccines and Immunotherapeutics, 2018, 14, 2116-2127.	3.3	17
115	Characterization of the Neutralizing Antibody Response in a Case of Genetically Linked HIV Superinfection. Journal of Infectious Diseases, 2018, 217, 1530-1534.	4.0	6
116	Novel Vaccine Technologies. JAMA - Journal of the American Medical Association, 2018, 319, 1431.	7.4	73
117	Is It Possible to Develop a â€œUniversalâ€•Influenza Virus Vaccine?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a029413.	5.5	34
118	Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet, The, 2018, 391, 552-562.	13.7	235
119	Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1â€“4. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12265-12270.	7.1	70
120	HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. PLoS Pathogens, 2018, 14, e1007431.	4.7	36
121	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. Immunity, 2018, 49, 1162-1174.e8.	14.3	61
122	Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge. PLoS Pathogens, 2018, 14, e1007395.	4.7	37
123	HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure. Immunity, 2018, 48, 855-871.	14.3	277
124	Glycoengineering HIV-1 Env creates â€˜superchargedâ€™ and â€˜hybridâ€™ glycans to increase neutralizing antibody potency, breadth and saturation. PLoS Pathogens, 2018, 14, e1007024.	4.7	22
125	Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV. PLoS Pathogens, 2018, 14, e1007159.	4.7	46
126	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nature Medicine, 2018, 24, 857-867.	30.7	256

#	Article	IF	Citations
127	Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Medicine, 2018, 15, e1002493.	8.4	174
128	Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. PLoS Pathogens, 2018, 14, e1006860.	4.7	68
129	Accumulation of follicular CD8+ T cells in pathogenic SIV infection. Journal of Clinical Investigation, 2018, 128, 2089-2103.	8.2	43
130	Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. PLoS ONE, 2018, 13, e0193773.	2.5	24
131	Chimpanzee Adenovirus Vector Ebola Vaccine. New England Journal of Medicine, 2017, 376, 928-938.	27.0	243
132	Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. Science Translational Medicine, 2017, 9, .	12.4	135
133	Use of broadly neutralizing antibodies for <scp>HIV</scp>â€1 prevention. Immunological Reviews, 2017, 275, 296-312.	6.0	131
134	The quest for an antibodyâ€based <scp>HIV</scp> vaccine. Immunological Reviews, 2017, 275, 5-10.	6.0	91
135	Antibodyomics: bioinformatics technologies for understanding Bâ€cell immunity to <scp>HIV</scp>â€1. Immunological Reviews, 2017, 275, 108-128.	6.0	32
136	Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. Journal of Virology, 2017, 91, .	3.4	81
137	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Science Immunology, 2017, 2, .	11.9	119
138	Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach. Immunity, 2017, 46, 804-817.e7.	14.3	107
139	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. Cell Reports, 2017, 19, 719-732.	6.4	160
140	Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity. Journal of Biological Chemistry, 2017, 292, 10197-10219.	3.4	29
141	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. Journal of Virology, 2017, 91, .	3.4	40
142	Staged induction of HIV-1 glycanâ€"dependent broadly neutralizing antibodies. Science Translational Medicine, 2017, 9, .	12.4	212
143	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Science Translational Medicine, 2017, 9, .	12.4	81
144	Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. Nature Chemical Biology, 2017, 13, 1115-1122.	8.0	110

#	Article	IF	Citations
145	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science, 2017, 358, 85-90.	12.6	225
146	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Science Translational Medicine, 2017, 9, .	12.4	106
147	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science Translational Medicine, 2017, 9, .	12.4	87
148	Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8614-8619.	7.1	42
149	Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. Journal of Virology, 2017, 91, .	3.4	38
150	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. Cell Reports, 2017, 21, 3681-3690.	6.4	97
151	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. Statistical Communications in Infectious Diseases, 2017, 9, .	0.2	62
152	Gene-Specific Substitution Profiles Describe the Types and Frequencies of Amino Acid Changes during Antibody Somatic Hypermutation. Frontiers in Immunology, 2017, 8, 537.	4.8	82
153	Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. PLoS Pathogens, 2017, 13, e1006148.	4.7	51
154	Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. PLoS Medicine, 2017, 14, e1002435.	8.4	104
155	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Nature Communications, 2017, 8, 1732.	12.8	76
156	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. PLoS ONE, 2017, 12, e0185959.	2.5	27
157	Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus. PLoS ONE, 2017, 12, e0186854.	2.5	42
158	Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathogens, 2017, 13, e1006074.	4.7	33
159	SONAR: A High-Throughput Pipeline for Inferring Antibody Ontogenies from Longitudinal Sequencing of B Cell Transcripts. Frontiers in Immunology, 2016, 7, 372.	4.8	67
160	Effects of Darwinian Selection and Mutability on Rate of Broadly Neutralizing Antibody Evolution during HIV-1 Infection. PLoS Computational Biology, 2016, 12, e1004940.	3.2	35
161	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathogens, 2016, 12, e1005520.	4.7	150
162	Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. PLoS Pathogens, 2016, 12, e1005537.	4.7	51

#	Article	IF	Citations
163	Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor. Immunity, 2016, 44, 939-950.	14.3	85
164	HIV Immunology Goes Out On a Limb. Immunity, 2016, 44, 1088-1090.	14.3	2
165	Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. Cell, 2016, 165, 813-826.	28.9	379
166	A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature, 2016, 533, 105-109.	27.8	281
167	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. Journal of Virology, 2016, 90, 5899-5914.	3.4	62
168	Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science, 2016, 352, 828-833.	12.6	310
169	Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant. Bioconjugate Chemistry, 2016, 27, 2372-2385.	3.6	44
170	Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell, 2016, 166, 1471-1484.e18.	28.9	198
171	Rapid development of a DNA vaccine for Zika virus. Science, 2016, 354, 237-240.	12.6	348
172	Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding. Journal of Virology, 2016, 90, 10574-10586.	3.4	35
173	Somatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing Antibodies. Structure, 2016, 24, 1346-1357.	3.3	35
174	Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nature Structural and Molecular Biology, 2016, 23, 811-820.	8.2	110
175	Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype. Cell Reports, 2016, 16, 1485-1491.	6.4	190
176	Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell, 2016, 166, 609-623.	28.9	270
177	Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. Immunity, 2016, 45, 1108-1121.	14.3	304
178	Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. New England Journal of Medicine, 2016, 375, 2037-2050.	27.0	391
179	An HIV-1 Envâ€“Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes. Journal of Immunology, 2016, 197, 3982-3998.	0.8	17
180	Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination. Nature Medicine, 2016, 22, 1456-1464.	30.7	271

#	Article	IF	Citations
181	Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nature Medicine, 2016, 22, 362-368.	30.7	163
182	High-Resolution Longitudinal Study of HIV-1 Env Vaccineâ€“Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence. Journal of Immunology, 2016, 196, 3729-3743.	0.8	26
183	Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science, 2016, 351, 1339-1342.	12.6	370
184	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. Cell, 2016, 165, 449-463.	28.9	305
185	Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody. Journal of Virology, 2016, 90, 2740-2755.	3.4	58
186	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nature Structural and Molecular Biology, 2016, 23, 81-90.	8.2	162
187	In vitro reconstitution of B cell receptorâ€“antigen interactions to evaluate potential vaccine candidates. Nature Protocols, 2016, 11, 193-213.	12.0	51
188	Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. Journal of Virology, 2016, 90, 1321-1332.	3.4	68
189	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. Journal of Virology, 2016, 90, 76-91.	3.4	205
190	Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8. PLoS ONE, 2016, 11, e0157409.	2.5	44
191	A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus. PLoS ONE, 2015, 10, e0128779.	2.5	38
192	Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env. Journal of Virology, 2015, 89, 5318-5329.	3.4	125
193	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell, 2015, 161, 1280-1292.	28.9	305
194	Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Science Translational Medicine, 2015, 7, 319ra206.	12.4	390
195	Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet, The, 2015, 385, 1545-1554.	13.7	109
196	HIV-1 Fitness Cost Associated with Escape from the VRC01 Class of CD4 Binding Site Neutralizing Antibodies. Journal of Virology, 2015, 89, 4201-4213.	3.4	121
197	Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes. Journal of Virology, 2015, 89, 2659-2671.	3.4	123
198	Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. PLoS Pathogens, 2015, 11, e1004932.	4.7	141

#	Article	IF	Citations
199	Evaluation of candidate vaccine approaches for MERS-CoV. Nature Communications, 2015, 6, 7712.	12.8	258
200	Diversion of HIV-1 vaccineâ€“induced immunity by gp41-microbiota cross-reactive antibodies. Science, 2015, 349, aab1253.	12.6	191
201	Quality and quantity of T _{FH} cells are critical for broad antibody development in SHIV _{AD8} infection. Science Translational Medicine, 2015, 7, 298ra120.	12.4	119
202	The modern era of HIV-1 vaccine development. Science, 2015, 349, 139-140.	12.6	36
203	Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nature Structural and Molecular Biology, 2015, 22, 522-531.	8.2	333
204	Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization. Nature Communications, 2015, 6, 6565.	12.8	77
205	Diverse Antibody Genetic and Recognition Properties Revealed following HIV-1 Envelope Glycoprotein Immunization. Journal of Immunology, 2015, 194, 5903-5914.	0.8	24
206	Antibody responses to envelope glycoproteins in HIV-1 infection. Nature Immunology, 2015, 16, 571-576.	14.5	364
207	Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. Cell, 2015, 161, 470-485.	28.9	226
208	Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. Journal of Virology, 2015, 89, 5895-5903.	3.4	92
209	Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development. Vaccine, 2015, 33, 7344-7351.	3.8	16
210	Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell, 2015, 162, 1090-1100.	28.9	278
211	Activation and lysis of human CD4 cells latently infected with HIV-1. Nature Communications, 2015, 6, 8447.	12.8	88
212	Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. Journal of Virology, 2015, 89, 8334-8345.	3.4	100
213	Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nature Medicine, 2015, 21, 1332-1336.	30.7	215
214	Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nature Medicine, 2015, 21, 1065-1070.	30.7	567
215	Editorial overview: Vaccines: Vaccines for cancer and infectious diseases. Current Opinion in Immunology, 2015, 35, v-vii.	5.5	1
216	Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas. MBio, 2015, 6, .	4.1	25

#	Article	IF	Citations
217	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host and Microbe, 2015, 18, 354-362.	11.0	66
218	Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Science Translational Medicine, 2014, 6, 243ra88.	12.4	222
219	HIV-1 Receptor Binding Site-Directed Antibodies Using a VH1-2 Gene Segment Orthologue Are Activated by Env Trimer Immunization. PLoS Pathogens, 2014, 10, e1004337.	4.7	23
220	Structural Basis for HIV-1 Neutralization by 2F5-Like Antibodies m66 and m66.6. Journal of Virology, 2014, 88, 2426-2441.	3.4	41
221	Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. Journal of Immunological Methods, 2014, 409, 131-146.	1.4	435
222	Antibodies VRC01 and 10E8 Neutralize HIV-1 with High Breadth and Potency Even with Ig-Framework Regions Substantially Reverted to Germline. Journal of Immunology, 2014, 192, 1100-1106.	0.8	86
223	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature, 2014, 509, 55-62.	27.8	681
224	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature, 2014, 505, 502-508.	27.8	140
225	Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. Journal of Experimental Medicine, 2014, 211, 2061-2074.	8.5	297
226	Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody <i>In Vitro</i> Improves Protection against Lentiviral Infection <i>In Vivo</i>. Journal of Virology, 2014, 88, 12669-12682.	3.4	248
227	Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. Journal of Virology, 2014, 88, 2489-2507.	3.4	274
228	Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies. Cell Host and Microbe, 2014, 16, 304-313.	11.0	137
229	Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. Cell, 2014, 158, 481-491.	28.9	266
230	Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature, 2014, 514, 642-645.	27.8	308
231	Impact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies. Journal of Virology, 2014, 88, 12623-12643.	3.4	75
232	Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet, The, 2014, 384, 2046-2052.	13.7	206
233	Single-Cell and Deep Sequencing of IgG-Switched Macaque B Cells Reveal a Diverse Ig Repertoire following Immunization. Journal of Immunology, 2014, 192, 3637-3644.	0.8	55
234	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature, 2014, 514, 455-461.	27.8	702

#	Article	IF	Citations
235	Hyperglycosylated Stable Core Immunogens Designed To Present the CD4 Binding Site Are Preferentially Recognized by Broadly Neutralizing Antibodies. Journal of Virology, 2014, 88, 14002-14016.	3.4	43
236	Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nature Medicine, 2014, 20, 1126-1129.	30.7	311
237	Broad and potent HIV-1 neutralization by a human antibody that binds the gp41â€“gp120 interface. Nature, 2014, 515, 138-142.	27.8	400
238	Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. Aids, 2014, 28, 163-169.	2.2	334
239	An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. Journal of Clinical Investigation, 2014, 124, 1835-1843.	8.2	93
240	Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies. Immunity, 2013, 39, 245-258.	14.3	332
241	Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nature Reviews Immunology, 2013, 13, 693-701.	22.7	302
242	Structural Basis for Highly Effective HIV-1 Neutralization by CD4-Mimetic Miniproteins Revealed by 1.5ÂÃ… Cocrystal Structure of gp120 and M48U1. Structure, 2013, 21, 1018-1029.	3.3	29
243	Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. New England Journal of Medicine, 2013, 369, 2083-2092.	27.0	518
244	Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04. Journal of Virology, 2013, 87, 2294-2306.	3.4	34
245	<scp>HIV</scp>â€1 neutralizing antibodies: understanding nature's pathways. Immunological Reviews, 2013, 254, 225-244.	6.0	442
246	Isolation of human monoclonal antibodies from peripheral blood B cells. Nature Protocols, 2013, 8, 1907-1915.	12.0	167
247	Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-ray and Thermodynamic Characterization. ACS Medicinal Chemistry Letters, 2013, 4, 338-343.	2.8	56
248	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature, 2013, 496, 469-476.	27.8	961
249	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. Immunity, 2013, 38, 176-186.	14.3	374
250	Mining the antibodyome for HIV-1â€“neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6470-6475.	7.1	142
251	Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization. Science, 2013, 340, 751-756.	12.6	213
252	Structural basis for diverse N-glycan recognition by HIV-1â€“neutralizing V1â€“V2â€“directed antibody PG16. Nature Structural and Molecular Biology, 2013, 20, 804-813.	8.2	257

#	Article	IF	Citations
253	De novo identification of VRC01 class HIV-1â€"neutralizing antibodies by next-generation sequencing of B-cell transcripts. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4088-97.	7.1	105
254	Residue-Level Prediction of HIV-1 Antibody Epitopes Based on Neutralization of Diverse Viral Strains. Journal of Virology, 2013, 87, 10047-10058.	3.4	64
255	Robust Neutralizing Antibodies Elicited by HIV-1 JRFL Envelope Glycoprotein Trimers in Nonhuman Primates. Journal of Virology, 2013, 87, 13239-13251.	3.4	63
256	Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial. PLoS ONE, 2013, 8, e53629.	2.5	165
257	N332-Directed Broadly Neutralizing Antibodies Use Diverse Modes of HIV-1 Recognition: Inferences from Heavy-Light Chain Complementation of Function. PLoS ONE, 2013, 8, e55701.	2.5	38
258	DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial. PLoS ONE, 2013, 8, e59340.	2.5	71
259	Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial. PLoS ONE, 2013, 8, e75665.	2.5	214
260	PGV04, an HIV-1 gp120 CD4 Binding Site Antibody, Is Broad and Potent in Neutralization but Does Not Induce Conformational Changes Characteristic of CD4. Journal of Virology, 2012, 86, 4394-4403.	3.4	109
261	BLyS-Mediated Modulation of Naive B Cell Subsets Impacts HIV Env-Induced Antibody Responses. Journal of Immunology, 2012, 188, 6018-6026.	0.8	34
262	Most rhesus macaques infected with the CCR5-tropic SHIV _{AD8} generate cross-reactive antibodies that neutralize multiple HIV-1 strains. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 19769-19774.	7.1	72
263	A Short Segment of the HIV-1 gp120 V1/V2 Region Is a Major Determinant of Resistance to V1/V2 Neutralizing Antibodies. Journal of Virology, 2012, 86, 8319-8323.	3.4	76
264	HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes. Journal of Virology, 2012, 86, 3393-3397.	3.4	71
265	Biochemically Defined HIV-1 Envelope Glycoprotein Variant Immunogens Display Differential Binding and Neutralizing Specificities to the CD4-binding Site. Journal of Biological Chemistry, 2012, 287, 5673-5686.	3.4	50
266	The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. AIDS Research and Human Retroviruses, 2012, 28, 1444-1457.	1.1	191
267	Anti-HIV B Cell Lines as Candidate Vaccine Biosensors. Journal of Immunology, 2012, 189, 4816-4824.	0.8	57
268	Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies. Immunity, 2012, 37, 412-425.	14.3	417
269	Gene-Based Vaccination with a Mismatched Envelope Protects against Simian Immunodeficiency Virus Infection in Nonhuman Primates. Journal of Virology, 2012, 86, 7760-7770.	3.4	31
270	HIV-1 Neutralizing Antibodies Display Dual Recognition of the Primary and Coreceptor Binding Sites and Preferential Binding to Fully Cleaved Envelope Glycoproteins. Journal of Virology, 2012, 86, 11231-11241.	3.4	61

#	Article	IF	Citations
271	Selection Pressure on HIV-1 Envelope by Broadly Neutralizing Antibodies to the Conserved CD4-Binding Site. Journal of Virology, 2012, 86, 5844-5856.	3.4	75
272	Pathogenicity and Mucosal Transmissibility of the R5-Tropic Simian/Human Immunodeficiency Virus SHIV _{AD8} in Rhesus Macaques: Implications for Use in Vaccine Studies. Journal of Virology, 2012, 86, 8516-8526.	3.4	47
273	Antibody-Dependent Cellular Cytotoxicity against Primary HIV-Infected CD4⁺T Cells Is Directly Associated with the Magnitude of Surface IgG Binding. Journal of Virology, 2012, 86, 8672-8680.	3.4	97
274	Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature, 2012, 491, 406-412.	27.8	753
275	The Development of CD4 Binding Site Antibodies during HIV-1 Infection. Journal of Virology, 2012, 86, 7588-7595.	3.4	123
276	Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design. Journal of Virology, 2012, 86, 4688-4692.	3.4	159
277	Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5663-5668.	7.1	222
278	High-Resolution Definition of Vaccine-Elicited B Cell Responses Against the HIV Primary Receptor Binding Site. Science Translational Medicine, 2012, 4, 142ra96.	12.4	108
279	Somatic populations of PGT135â€“137 HIV-1-neutralizing antibodies identified by 454 pyrosequencing and bioinformatic. Frontiers in Microbiology, 2012, 3, 315.	3.5	70
280	The changing face of HIV vaccine research. Journal of the International AIDS Society, 2012, 15, 17407.	3.0	47
281	Structure-Based Design, Synthesis, and Characterization of Dual Hotspot Small-Molecule HIV-1 Entry Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 4382-4396.	6.4	90
282	A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial. Journal of Infectious Diseases, 2011, 203, 1396-1404.	4.0	138
283	Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01. Journal of Virology, 2011, 85, 8954-8967.	3.4	209
284	Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. Journal of Virology, 2011, 85, 9998-10009.	3.4	393
285	Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals. Journal of Virology, 2011, 85, 11502-11519.	3.4	168
286	Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing. Science, 2011, 333, 1593-1602.	12.6	788
287	DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infectious Diseases, The, 2011, 11, 916-924.	9.1	174
288	Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1. Journal of Virology, 2011, 85, 2524-2535.	3.4	46

#	Article	IF	Citations
289	HIV Type 1 Env Precursor Cleavage State Affects Recognition by Both Neutralizing and Nonneutralizing gp41 Antibodies. AIDS Research and Human Retroviruses, 2011, 27, 877-887.	1.1	57
290	Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies Identified from a Patient with 2F5-Like Antibodies. Journal of Virology, 2011, 85, 11401-11408.	3.4	80
291	Antibody-Dependent Cell-Mediated Cytotoxicity in Simian Immunodeficiency Virus-Infected Rhesus Monkeys. Journal of Virology, 2011, 85, 6906-6912.	3.4	67
292	Rational Design of Vaccines to Elicit Broadly Neutralizing Antibodies to HIV-1. Cold Spring Harbor Perspectives in Medicine, 2011, 1, a007278-a007278.	6.2	135
293	The <i>TRIM5</i> Gene Modulates Penile Mucosal Acquisition of Simian Immunodeficiency Virus in Rhesus Monkeys. Journal of Virology, 2011, 85, 10389-10398.	3.4	43
294	Antibody-Dependent Cell-Mediated Viral Inhibition Emerges after Simian Immunodeficiency Virus SIVmac251 Infection of Rhesus Monkeys Coincident with gp140-Binding Antibodies and Is Effective against Neutralization-Resistant Viruses. Journal of Virology, 2011, 85, 5465-5475.	3.4	47
295	Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature, 2011, 480, 336-343.	27.8	794
296	Immunotypes of a Quaternary Site of HIV-1 Vulnerability and Their Recognition by Antibodies. Journal of Virology, 2011, 85, 4578-4585.	3.4	43
297	Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Science Translational Medicine, 2011, 3, 81ra36.	12.4	179
298	Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses. PLoS ONE, 2010, 5, e9015.	2.5	125
299	Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. Journal of Experimental Medicine, 2010, 207, 2003-2017.	8.5	106
300	Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables. Journal of Virology, 2010, 84, 1631-1636.	3.4	304
301	Influence of Novel CD4 Binding-Defective HIV-1 Envelope Glycoprotein Immunogens on Neutralizing Antibody and T-Cell Responses in Nonhuman Primates. Journal of Virology, 2010, 84, 1683-1695.	3.4	44
302	Relationship between Antibody 2F5 Neutralization of HIV-1 and Hydrophobicity of Its Heavy Chain Third Complementarity-Determining Region. Journal of Virology, 2010, 84, 2955-2962.	3.4	106
303	The Role of Antibodies in HIV Vaccines. Annual Review of Immunology, 2010, 28, 413-444.	21.8	356
304	Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01. Science, 2010, 329, 811-817.	12.6	1,050
305	Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. Science, 2010, 329, 856-861.	12.6	1,600
306	Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1. Journal of Virology, 2010, 84, 8098-8110.	3.4	209

#	Article	IF	Citations
307	Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies. Journal of Virology, 2010, 84, 1439-1452.	3.4	589
308	Human Immunodeficiency Virus Type 1 Env Trimer Immunization of Macaques and Impact of Priming with Viral Vector or Stabilized Core Protein. Journal of Virology, 2009, 83, 540-551.	3.4	54
309	Mechanism of Human Immunodeficiency Virus Type 1 Resistance to Monoclonal Antibody b12 That Effectively Targets the Site of CD4 Attachment. Journal of Virology, 2009, 83, 10892-10907.	3.4	86
310	Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors. Journal of Virology, 2009, 83, 8925-8937.	3.4	170
311	Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals. Journal of Virology, 2009, 83, 1045-1059.	3.4	238
312	Structure-Based Stabilization of HIV-1 gp120 Enhances Humoral Immune Responses to the Induced Co-Receptor Binding Site. PLoS Pathogens, 2009, 5, e1000445.	4.7	113
313	Enhanced Exposure of the CD4-Binding Site to Neutralizing Antibodies by Structural Design of a Membrane-Anchored Human Immunodeficiency Virus Type 1 gp120 Domain. Journal of Virology, 2009, 83, 5077-5086.	3.4	43
314	Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. Journal of Experimental Medicine, 2009, 206, 1117-1134.	8.5	295
315	Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies. Journal of Virology, 2009, 83, 188-199.	3.4	297
316	Broad Neutralization of Human Immunodeficiency Virus Type 1 Mediated by Plasma Antibodies against the gp41 Membrane Proximal External Region. Journal of Virology, 2009, 83, 11265-11274.	3.4	93
317	A method for identification of HIV gp140 binding memory B cells in human blood. Journal of Immunological Methods, 2009, 343, 65-67.	1.4	204
318	Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature, 2009, 458, 636-640.	27.8	806
319	Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nature Medicine, 2009, 15, 866-870.	30.7	390
320	Mining the B Cell Repertoire for Broadly Neutralizing Monoclonal Antibodies to HIV-1. Cell Host and Microbe, 2009, 6, 292-294.	11.0	22
321	Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120. Science, 2009, 326, 1123-1127.	12.6	271
322	Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?. Current Opinion in HIV and AIDS, 2009, 4, 347-351.	3.8	47
323	A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine, 2008, 26, 6338-6343.	3.8	230
324	Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C. Journal of Virology, 2008, 82, 11651-11668.	3.4	337

#	Article	IF	Citations
325	Cross-Reactive Human Immunodeficiency Virus Type 1-Neutralizing Human Monoclonal Antibody That Recognizes a Novel Conformational Epitope on gp41 and Lacks Reactivity against Self-Antigens. Journal of Virology, 2008, 82, 6869-6879.	3.4	41
326	B Cell Recognition of the Conserved HIV-1 Co-Receptor Binding Site Is Altered by Endogenous Primate CD4. PLoS Pathogens, 2008, 4, e1000171.	4.7	57
327	No Evidence for Consistent Virus-Specific Immunity in Simian Immunodeficiency Virus-Exposed, Uninfected Rhesus Monkeys. Journal of Virology, 2007, 81, 12368-12374.	3.4	51
328	A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial. Journal of Infectious Diseases, 2007, 196, 1732-1740.	4.0	175
329	Lysis of Human Immunodeficiency Virus Type 1 by a Specific Secreted Human Phospholipase A 2. Journal of Virology, 2007, 81, 1444-1450.	3.4	37
330	Characterization of Human Immunodeficiency Virus Type 1 Monomeric and Trimeric gp120 Glycoproteins Stabilized in the CD4-Bound State: Antigenicity, Biophysics, and Immunogenicity. Journal of Virology, 2007, 81, 5579-5593.	3.4	101
331	Dendritic Cells Are Less Susceptible to Human Immunodeficiency Virus Type 2 (HIV-2) Infection than to HIV-1 Infection. Journal of Virology, 2007, 81, 13486-13498.	3.4	49
332	Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine, 2007, 25, 4085-4092.	3.8	134
333	Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nature Medicine, 2007, 13, 1032-1034.	30.7	364
334	Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology, 2006, 350, 34-47.	2.4	98
335	Gene transfer in humans using a conditionally replicating lentiviral vector. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17372-17377.	7.1	452
336	Preserved CD4+ Central Memory T Cells and Survival in Vaccinated SIV-Challenged Monkeys. Science, 2006, 312, 1530-1533.	12.6	343
337	Virus-Specific Cellular Immune Correlates of Survival in Vaccinated Monkeys after Simian Immunodeficiency Virus Challenge. Journal of Virology, 2006, 80, 10950-10956.	3.4	53
338	Preservation of Functional Virus-Specific Memory CD8+ T Lymphocytes in Vaccinated, Simian Human Immunodeficiency Virus-Infected Rhesus Monkeys. Journal of Immunology, 2006, 176, 5338-5345.	0.8	34
339	Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys. Journal of Virology, 2005, 79, 2956-2963.	3.4	120
340	A Human T-Cell Leukemia Virus Type 1 Regulatory Element Enhances the Immunogenicity of Human Immunodeficiency Virus Type 1 DNA Vaccines in Mice and Nonhuman Primates. Journal of Virology, 2005, 79, 8828-8834.	3.4	162
341	Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines. Journal of Virology, 2005, 79, 10103-10107.	3.4	233
342	Dysfunction of Simian Immunodeficiency Virus/Simian Human Immunodeficiency Virus-Induced IL-2 Expression by Central Memory CD4+ T Lymphocytes. Journal of Immunology, 2005, 174, 4753-4760.	0.8	27

#	Article	IF	Citations
343	Pathogenicity of Simian-Human Immunodeficiency Virus SHIV-89.6P and SIVmac Is Attenuated in Cynomolgus Macaques and Associated with Early T-Lymphocyte Responses. Journal of Virology, 2005, 79, 8878-8885.	3.4	120
344	Vaccine-Elicited Memory Cytotoxic T Lymphocytes Contribute to Mamu-A*01-Associated Control of Simian/Human Immunodeficiency Virus 89.6P Replication in Rhesus Monkeys. Journal of Virology, 2005, 79, 4580-4588.	3.4	27
345	Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells. Journal of Experimental Medicine, 2005, 201, 2023-2033.	8.5	183
346	Neutralizing Antibodies Elicited by Immunization of Monkeys with DNA Plasmids and Recombinant Adenoviral Vectors Expressing Human Immunodeficiency Virus Type 1 Proteins. Journal of Virology, 2005, 79, 771-779.	3.4	100
347	Replication-Defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and Humoral Immune Responses in Nonhuman Primates. Journal of Virology, 2005, 79, 6516-6522.	3.4	136
348	Differential Susceptibility to Human Immunodeficiency Virus Type 1 Infection of Myeloid and Plasmacytoid Dendritic Cells. Journal of Virology, 2005, 79, 8861-8869.	3.4	192
349	Biochemical and Immunogenic Characterization of Soluble Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Expressed by Semliki Forest Virus. Journal of Virology, 2005, 79, 10902-10914.	3.4	35
350	Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. Journal of Virology, 2005, 79, 10108-10125.	3.4	1,025
351	Effects of Antibody on Viral Kinetics in Simian/Human Immunodeficiency Virus Infection: Implications for Vaccination. Journal of Virology, 2004, 78, 5520-5522.	3.4	23
352	Immunogenicity of Constrained Monoclonal Antibody A32-Human Immunodeficiency Virus (HIV) Env gp120 Complexes Compared to That of Recombinant HIV Type 1 gp120 Envelope Glycoproteins. Journal of Virology, 2004, 78, 5270-5278.	3.4	40
353	Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope. Journal of Virology, 2004, 78, 10724-10737.	3.4	452
354	The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope. Journal of Virology, 2004, 78, 2394-2404.	3.4	111
355	Heterologous Envelope Immunogens Contribute to AIDS Vaccine Protection in Rhesus Monkeys. Journal of Virology, 2004, 78, 7490-7497.	3.4	126
356	Selective Modification of Variable Loops Alters Tropism and Enhances Immunogenicity of Human Immunodeficiency Virus Type 1 Envelope. Journal of Virology, 2004, 78, 4029-4036.	3.4	68
357	The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature, 2003, 426, 853-857.	27.8	219
358	HIV-1: nature's master of disguise. Nature Medicine, 2003, 9, 393-394.	30.7	49
359	Specific Antibody Responses to Vaccination with Bivalent CM235/SF2 gp120: Detection of Homologous and Heterologous Neutralizing Antibody to Subtype E (CRF01.AE) HIV Type 1. AIDS Research and Human Retroviruses, 2003, 19, 807-816.	1.1	27
360	Cellular Immunity Elicited by Human Immunodeficiency Virus Type 1/ Simian Immunodeficiency Virus DNA Vaccination Does Not Augment the Sterile Protection Afforded by Passive Infusion of Neutralizing Antibodies. Journal of Virology, 2003, 77, 10348-10356.	3.4	50

#	Article	IF	Citations
361	Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. Aids, 2003, 17, 2521-2527.	2.2	64
362	Defining the Protective Antibody Response for HIV-1. Current Molecular Medicine, 2003, 3, 209-216.	1.3	121
363	Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T Cells. Journal of Virology, 2002, 76, 4810-4821.	3.4	106
364	Elicitation of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Mucosal Compartments of Rhesus Monkeys by Systemic Vaccination. Journal of Virology, 2002, 76, 11484-11490.	3.4	47
365	Selective Increases in HIV-Specific Neutralizing Antibody and Partial Reconstitution of Cellular Immune Responses during Prolonged, Successful Drug Therapy of HIV Infection. AIDS Research and Human Retroviruses, 2001, 17, 1021-1034.	1.1	26
366	Vaccines for the prevention of HIV-1 disease. Current Opinion in Immunology, 2001, 13, 489-494.	5.5	59
367	Human Dendritic Cells as Targets of Dengue Virus Infection. Journal of Investigative Dermatology Symposium Proceedings, 2001, 6, 219-224.	0.8	149
368	Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naÃ¯ve HIV-1 infected US military personnel. Aids, 2000, 14, 1009-1015.	2.2	103
369	Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Medicine, 2000, 6, 207-210.	30.7	1,237
370	Human skin Langerhans cells are targets of dengue virus infection. Nature Medicine, 2000, 6, 816-820.	30.7	586
371	Canarypox Virus-Induced Maturation of Dendritic Cells Is Mediated by Apoptotic Cell Death and Tumor Necrosis Factor Alpha Secretion. Journal of Virology, 2000, 74, 11329-11338.	3.4	108
372	Herpes Simplex Virus Vaccinesâ€" Why Don't Antibodies Protect?. JAMA - Journal of the American Medical Association, 1999, 282, 379.	7.4	30
373	Development of Calibrated Viral Load Standards for Group M Subtypes of Human Immunodeficiency Virus Type 1 and Performance of an Improved AMPLICOR HIV-1 MONITOR Test with Isolates of Diverse Subtypes. Journal of Clinical Microbiology, 1999, 37, 2557-2563.	3.9	124
374	Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies. Journal of Virology, 1999, 73, 4009-4018.	3.4	725
375	Cross-Subtype Neutralizing Antibodies Induced in Baboons by a Subtype E gp120 Immunogen Based on an R5 Primary Human Immunodeficiency Virus Type 1 Envelope. Journal of Virology, 1999, 73, 4640-4650.	3.4	46
376	A Human Monoclonal Antibody Specific for the V3 Loop of HIV Type 1 Clade E Cross-Reacts with Other HIV Type 1 Clades. AIDS Research and Human Retroviruses, 1998, 14, 213-221.	1.1	25
377	Neutralizing Antibodies from the Sera of Human Immunodeficiency Virus Type 1-Infected Individuals Bind to Monomeric gp120 and Oligomeric gp140. Journal of Virology, 1998, 72, 9656-9667.	3.4	36
378	Neutralizing Monoclonal Antibodies Block Human Immunodeficiency Virus Type 1 Infection of Dendritic Cells and Transmission to T Cells. Journal of Virology, 1998, 72, 9788-9794.	3.4	80

#	Article	IF	Citations
379	Exclusive and Persistent Use of the Entry Coreceptor CXCR4 by Human Immunodeficiency Virus Type 1 from a Subject Homozygous for <i>CCR5</i> Î”32. Journal of Virology, 1998, 72, 6040-6047.	3.4	163
380	The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nature Medicine, 1997, 3, 338-340.	30.7	480
381	Human Immunodeficiency Virus Type 1 Neutralizing Antibody Serotyping Using Serum Pools and an Infectivity Reduction Assay. AIDS Research and Human Retroviruses, 1996, 12, 1319-1328.	1.1	77
382	Induction of HIV Type 1 Neutralizing and<i>env</i>-CD4 Blocking Antibodies by Immunization with Genetically Engineered HIV Type 1-Like Particles Containing Unprocessed gp160 Glycoproteins. AIDS Research and Human Retroviruses, 1995, 11, 1187-1195.	1.1	21
383	Two Antigenically Distinct Subtypes of Human Immunodeficiency Virus Type 1: Viral Genotype Predicts Neutralization Serotype. Journal of Infectious Diseases, 1994, 169, 48-54.	4.0	195
384	High throughput HIV-1 microneutralization assay. Protocol Exchange, 0, , .	0.3	16